BNP Paribas Financial Markets
BTAI

BNP Paribas Financial Markets’s BioXcel Therapeutics BTAI Stock Holding History

BNP Paribas Financial Markets’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17 Sell
12
-47
-80% -$55 ﹤0.01% 5859
2026
Q1 		$79 Buy
59
+47
+392% +$77 ﹤0.01% 5695
2025
Q4 		$19 Sell
12
-27
-69% -$56 ﹤0.01% 5671
2025
Q3 		$100 Sell
39
-5
-11% -$16 ﹤0.01% 5434
2025
Q2 		$80 Hold
44
– – ﹤0.01% 5335
2025
Q1 		$89 Sell
44
-101
-70% -$377 ﹤0.01% 5263
2024
Q4 		$868 Sell
145
-2,629
-95% -$22K ﹤0.01% 5102
2024
Q3 		$27.1K Sell
2,774
-14,297
-84% -$192K ﹤0.01% 3719
2024
Q2 		$350K Buy
17,071
+15,712
+1,156% +$526K ﹤0.01% 2839
2024
Q1 		$61.3K Sell
1,359
-105
-7% -$5.01K ﹤0.01% 3548
2023
Q4 		$69.1K Sell
1,464
-3,302
-69% -$184K ﹤0.01% 3496
2023
Q3 		$193K Buy
4,766
+391
+9% +$39.5K ﹤0.01% 3107
2023
Q2 		$466K Sell
4,375
-2,736
-38% -$911K ﹤0.01% 2618
2023
Q1 		$2.12M Buy
7,111
+4,900
+222% +$2.09M ﹤0.01% 1777
2022
Q4 		$760K Sell
2,211
-1,162
-34% -$281K ﹤0.01% 2329
2022
Q3 		$638K Sell
3,373
-562
-14% -$130K ﹤0.01% 2811
2022
Q2 		$831K Sell
3,935
-1,271
-24% -$267K ﹤0.01% 2324
2022
Q1 		$1.74M Buy
5,206
+1,029
+25% +$298K ﹤0.01% 1931
2021
Q4 		$1.36M Buy
4,177
+2,597
+164% +$1.11M ﹤0.01% 2369
2021
Q3 		$767K Buy
1,580
+464
+42% +$204K ﹤0.01% 2525
2021
Q2 		$519K Buy
1,116
+556
+99% +$303K ﹤0.01% 2515
2021
Q1 		$386K Buy
560
+473
+544% +$381K ﹤0.01% 2714
2020
Q4 		$64.4K Sell
87
-102
-54% -$79.5K ﹤0.01% 3435
2020
Q3 		$131K Buy
189
+50
+36% +$37.5K ﹤0.01% 2971
2020
Q2 		$118K Buy
139
+8
+6% +$5.22K ﹤0.01% 2702
2020
Q1 		$46.7K Buy
131
+75
+134% +$27K ﹤0.01% 3568
2019
Q4 		$13K Buy
56
+37
+195% +$3.72K ﹤0.01% 4098
2019
Q3 		$2.1K Buy
19
+18
+1,800% +$2.84K ﹤0.01% 4355
2019
Q2 		$175 Buy
+1
New +$169 ﹤0.01% 4462

Other funds holding BTAI

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BNP Paribas Financial Markets's BTAI Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its BioXcel Therapeutics (BTAI) stake by 80% in Q2 2026, selling an estimated $55 and leaving 12 shares worth $17. The position accounts for ﹤0.01% of the portfolio, ranked #5859.

BNP Paribas Financial Markets first reported a position in BTAI in Q2 2019 and has held it in 29 quarters since. The position peaked at $2.12M in Q1 2023. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • BNP Paribas Financial Markets held 12 shares of BioXcel Therapeutics worth $17 as of Q2 2026.
  • BNP Paribas Financial Markets sold 47 BioXcel Therapeutics shares in Q2 2026, an estimated $55.
  • BioXcel Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5859 holding.
  • BNP Paribas Financial Markets first reported a position in BioXcel Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • BNP Paribas Financial Markets's BioXcel Therapeutics position peaked at $2.12M in Q1 2023.
  • 47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.